JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266701

Human GPATCH4 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

GPATCH4 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 3 and 2 bp deletion in exon 3.

View Alternative Names

G patch domain containing 4, G patch domain containing protein 4, GPATC4

2 Images
Sanger Sequencing - Human GPATCH4 knockout HEK-293T cell line (AB266701)
  • Sanger seq

Unknown

Sanger Sequencing - Human GPATCH4 knockout HEK-293T cell line (AB266701)

Allele-1 : 16 bp deletion in exon 3

Sanger Sequencing - Human GPATCH4 knockout HEK-293T cell line (AB266701)
  • Sanger seq

Unknown

Sanger Sequencing - Human GPATCH4 knockout HEK-293T cell line (AB266701)

Allele-2 : 2 bp deletion in exon 3.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 3 and 2 bp deletion in exon 3

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266701-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266701 Human GPATCH4 knockout HEK-293T cell line", "number":"AB266701-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266701-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266701 Human GPATCH4 knockout HEK-293T cell line", "number":"AB266701-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
GPATCH4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The GPATCH4 protein also known as G patch domain-containing protein 4 is a member of the G-patch domain family and has a molecular mass of approximately 102 kDa. GPATCH4 plays a mechanical role in pre-mRNA splicing where it associates with RNA and other splicing factors. This protein is expressed in various tissues with particular high levels in testis and heart. Its exact localization and interaction partners within the cell are subject to ongoing research but the consensus finds GPATCH4 interacting directly with the RNA molecule.
Biological function summary

The GPATCH4 protein contributes to the regulation of RNA processing. It functions as a part of a larger ribonucleoprotein complex involved in the assembly and functionality of spliceosomes. The integration of GPATCH4 into this complex aids in the accurate and efficient splicing of pre-mRNA an essential process for gene expression regulation. Proper functioning of GPATCH4 ensures that diverse cellular processes requiring specific mRNA molecules proceed without error.

Pathways

GPATCH4 plays important roles in the pre-mRNA splicing pathway a critical component of gene expression. This pathway necessitates the involvement of several other proteins including SF3B1 and U2AF2 which work alongside GPATCH4 in the spliceosome assembly. GPATCH4 contributes to these complex interactions facilitating the precise removal of introns from pre-mRNA strands in both major and minor splicing pathways. This activity impacts how cells respond to different physiological conditions and external stimuli.

Abnormal functioning of GPATCH4 relates to cancer and certain cardiovascular conditions making it an interesting target for medical research. Studies suggest that misregulation of the splicing process in which GPATCH4 is involved can trigger oncogenesis potentially by affecting genes that control cell proliferation. In cardiovascular diseases changes in splicing profiles sometimes involving GPATCH4 lead to maladaptive cellular responses. Research into how GPATCH4 interacts with other proteins like SF3B1 can provide insights into these disorders' underlying mechanics offering potential avenues for therapeutic intervention.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com